2012 Nobel Laureates - Drs. Shinya Yamanaka and John Gurdon - Present
SAN FRANCISCO--(BUSINESS WIRE)-- Today’s Roddenberry International Symposium on Cellular Reprogramming in San Francisco will be Drs. Shinya Yamanaka and John Gurdon first public appearance together since being named 2012 Nobel Laureates, according to the ISSCR’s (International Society for Stem Cell Research) website. The Roddenberry International Symposium is a collaborative effort between the ISSCR and the Roddenberry Center for Stem Cell Biology and Medicine at the Gladstone Institutes.
The symposium explores the latest research on reprogramming mature cells (such as skin or fat cells) into pluripotent cells -- capable of differentiating into different types of body cells. These reprogrammed cells hold the promise of being applied in medical treatments for therapeutic gain in the future.
More than 25 of the world's top stem cell scientists -- from top global research institutions such as the National Institutes of Health, the California Institute for Regenerative Medicine, the Wellcome Trust Centre for Stem Cell Research, University of Cambridge, UCSF, Stanford, UCLA, MIT Kyoto University and Memorial Sloan-Kettering Cancer Center – have gathered to discuss recent research, advances and perspectives in cellular reprogramming.
Fluidigm Corporation is a gold sponsor of the event and is exhibiting its new C1™ Single-Cell AutoPrep System, as well as presenting three posters on current and future applications of its integrated fluidic chip technology for single-cell analysis.
Fluidigm is a key supplier to the scientific research community investigating stem cell genomic signatures down to the single-cell level. “We are proud to provide many of these institutions with tools that allow researchers to gather genomic information at the single-cell level,” said Gajus Worthington, Fluidigm President and Chief Executive Officer.
The conference emphasizes the important role that stem cells will have in advancing life science and medical understanding, ultimately with the goal of enhancing medical practices in the future. The Rodenberry Foundation, sponsor of this symposium, sees this work as a positive, important step in bringing to reality a number of concepts for better health options.
A pioneer and technology leader in single-cell genomics, Fluidigm has been supplying its BioMark™ and BioMark HD platforms to single-cell genomics researchers since 2007 and is proud to count among its customers many of the leading institutions in the world. Fluidigm’s new product, the C1 Single-Cell AutoPrep System, is the first and only genomic-focused single-cell capture and preparation device available on the market that allows researchers to study cell differentiation and measure individual cell responses to specific stimuli, both of which are particularly important to stem cell researchers.
“Our C1 Single-Cell AutoPrep System has enjoyed a very enthusiastic reception from the stem cell community due to its unique ability to capture and prepare individual cells for genomic characterization,” said Worthington. “We are delighted to once again sponsor an ISSCR event and enable the work that drives humanity to a better future as envisioned and supported by the Roddenberry Foundation,” he concluded.
Fluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including nine different commercial chips, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use).
For more information, please visit www.fluidigm.com.
Fluidigm, the Fluidigm logo, BioMark and C1 are trademarks or registered trademarks of Fluidigm Corporation.
Howard High - Press Relations